A clinical trial at Columbia University Irving Medical Center (CUIMC) has been designed to test cannabis efficacy to treat taxane-induced peripheral neuropathy (TIPN). The randomized placebo-controlled clinical trial, led by Diana Martinez, M.D., Professor of Psychiatry at CUIMC, and Margaret Haney, Ph.D., Professor of Neurobiology (in Psychiatry) at CUIMC, started enrolling patients in October 2019 and will use capsules containing a combination of THC and CBD, imported from Tilray in Canada. THC and CBD do not interfere with the efficacy of chemotherapeutic agents in vitro, and may even inhibit growth in breast tumor cell lines. This clinical trial is the first human study testing the effectiveness of medical cannabis to treat TIPN.
We are currently seeking funding to supplement this study to identify a novel biomarker that could predict cannabis efficacy and tolerability in the treatment of TIPN, and ultimately facilitate the use of precision medicine in future studies. These molecular markers may also provide information on the mechanism by which cannabis exerts its therapeutic effects, and could potentially be used as biomarkers for cannabis treatment efficacy in other disorders.
If you’re interested in supporting the biomarker add-on to this ongoing study, please contact us or donate now.Donate Now